Verition Fund Management
SLN

Verition Fund Management’s Silence Therapeutics SLN Stock Holding History

Verition Fund Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-24,123
Closed -$166K – 3673
2024
Q4 		$166K Buy
24,123
+12,733
+112% +$164K ﹤0.01% 3016
2024
Q3 		$207K Buy
+11,390
New +$212K ﹤0.01% 2871

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Verition Fund Management's SLN Position: Q1 2025 in Review

Verition Fund Management sold out of Silence Therapeutics (SLN) in Q1 2025, closing a stake of 24,123 shares — an estimated $166K sold.

Verition Fund Management first reported a position in SLN in Q3 2024 and held it in 2 quarters. The position peaked at $207K in Q3 2024. 59 funds tracked by Wall St. Rank hold SLN as of Q1 2025.

  • Verition Fund Management reported no remaining Silence Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Verition Fund Management sold 24,123 Silence Therapeutics shares in Q1 2025, an estimated $166K.
  • Verition Fund Management first reported a position in Silence Therapeutics in Q3 2024 and held it in 2 quarters.
  • Verition Fund Management's Silence Therapeutics position peaked at $207K in Q3 2024.
  • 59 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2025.

Based on Verition Fund Management's 13F filing for Q1 2025, filed 15 May 2025.